Accendra Health vs ePlus
ACH and PLUS side by side, both in professional and commercial equipment and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACH and PLUS compare
ePlus is the larger company, worth 227 times as much as Accendra Health ($2.5B against $11.2M).
ePlus grew revenue faster over the last twelve months (13.1% versus −7.1% for Accendra Health).
ePlus keeps more of each dollar of sales as profit, with a net margin of 5.2% compared with −6.7% at Accendra Health.
ePlus pays a dividend yielding 1.1%; Accendra Health does not pay one.
ePlus scores higher on the StockData Score (14 against 5 for Accendra Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACH | PLUS |
|---|---|---|
| Size and price | ||
| Market cap | $11.2M | $2.5B |
| Share price | $0.145 | $97.19 |
| Change, 1 year | −95.1% | 10.1% |
| Change, 5 years | −99.7% | 68.9% |
| Beta (5Y) | 1.42 | 0.99 |
| Employees | 6,500 | 2,148 |
| StockData Score | ||
| Total score | 5 | 14 (better) |
| Valuation score | 4 (better) | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 | 4 (better) |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 19.4× |
| P/S | 0.0× (better) | 1.0× |
| P/B | – | 2.3× |
| EV/EBITDA | 7.4× (better) | 10.7× |
| P/FCF | – | 80.3× |
| PEG | – | 4.94 |
| FCF yield | −1783% | 1.2% (better) |
| Fair value | $8.34 | $86.06 |
| Margin of safety | 98.3% (better) | −12.9% |
| Growth | ||
| Revenue growth (TTM) | −7.1% | 13.1% (better) |
| Revenue growth, 5Y average | −20.1% | 9.3% (better) |
| Net income growth (TTM) | – | 6.0% |
| EPS growth (TTM) | – | 7.3% |
| EPS growth, 5Y average | – | 12.7% |
| Profitability | ||
| Gross margin | 44.1% (better) | 25.4% |
| Operating margin | 0.17% | 7.0% (better) |
| Net margin | −6.7% | 5.2% (better) |
| FCF margin | −7.8% | 1.3% (better) |
| Return on equity | – | 12.2% |
| Return on invested capital | 0.24% | 18.7% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | 7.35 | – |
| Interest coverage | 0.0× | – |
| Current ratio | 0.41 | 1.99 (better) |
| Altman Z-score | 0.20 | 4.44 (better) |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 1.1% |
| Payout ratio | – | 20.8% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | 2.3% |
| Shareholder yield | 0.00% | 3.4% (better) |
| Ownership | ||
| Held by institutions | 81.1% | 96.6% |
| Held by insiders | 21.4% | 2.1% |
| Insider net buying, 12 months | – | −$2.3M |
| Short interest, % of float | 16.8% | 5.7% |
Go deeper
- ACH stock overview
- ACH income statement
- ACH valuation and score
- PLUS stock overview
- PLUS income statement
- PLUS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.